Nurix Therapeutics, Inc. NRIX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s other accrued liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported other accrued liabilities of $1.93M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s other accrued liabilities changed year-over-year?
- Nurix Therapeutics, Inc.'s other accrued liabilities decreased by 28.4% year-over-year, from $2.69M to $1.93M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s other accrued liabilities?
- Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s other accrued liabilities has grown at a 11.7% compound annual growth rate (CAGR), from $1.5M to $2.1M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.